Hydroxyethyl starch: a review of pharmacokinetics, pharmacodynamics, current products, and potential clinical risks, benefits, and use.
about
In vitro effects of 6 % hydroxyethyl starch 130/0.42 solution on feline whole blood coagulation measured by rotational thromboelastometry.Changes in Serum Creatinine Concentration and Acute Kidney Injury (AKI) Grade in Dogs Treated with Hydroxyethyl Starch 130/0.4 From 2013 to 2015.Controversies in the use of hydroxyethyl starch solutions in small animal emergency and critical care.Effects of Hydroxyethyl Starch 130/0.4 on Serum Creatinine Concentration and Development of Acute Kidney Injury in Nonazotemic Cats.Retrospective evaluation of the effects of administration of tetrastarch (hydroxyethyl starch 130/0.4) on plasma creatinine concentration in dogs (2010-2013): 201 dogs.Retrospective cohort study on the incidence of acute kidney injury and death following hydroxyethyl starch (HES 10% 250/0.5/5:1) administration in dogs (2007-2010).Current Trends in Volume Replacement Therapy and the Use of Synthetic Colloids in Small Animals-An Internet-Based Survey (2016).The swinging pendulum between consensus and controversy in veterinary emergency and critical care.Treatment of meloxicam overdose in a dog via therapeutic plasma exchange.Prevalence of and risk factors for intraoperative gastroesophageal reflux and postanesthetic vomiting and diarrhea in dogs undergoing general anesthesia.Comparison of the effects of a balanced crystalloid-based and a saline-based tetrastarch solution on canine whole blood coagulation and platelet function.Effects of 6% Tetrastarch and Lactated Ringer's Solution on Extravascular Lung Water and Markers of Acute Renal Injury in Hemorrhaged, Isoflurane-Anesthetized Healthy Dogs.Thromboelastometric assessment of hemostasis following hydroxyethyl starch (130/0.4) administration as a constant rate infusion in hypoalbuminemic dogs.
P2860
Q36086254-C1CF5E0A-DADB-478F-81CB-7EC78A57B21CQ37705220-C4D7FADF-17CC-42A9-83B9-542049C774A7Q38345631-7A0BB135-70BA-48D9-A809-558A8A4AE53FQ40061568-1C36F85D-0BA7-4767-847D-4BF0A39FAF1FQ40688216-EB95A3F7-047F-4274-B6ED-422C0F12CDDBQ41110540-CF81F429-1A52-4B36-8804-74B95B6922B0Q41475051-04BE350C-55CE-46B8-A7CB-73AD323A5424Q43487688-BB2DEBE9-409B-421F-931F-4884986F8D3EQ44872205-E72342B5-F17F-4F93-8728-394BA5A5B11BQ47292425-48CA9B4F-362A-4BFC-93D6-8E3AD4797685Q47356474-5EF5C244-F0CE-47B7-B15E-962B3AB450E0Q47698138-8797A1FF-E7BF-44E4-9156-395D7DB002BDQ49184956-FCAA9C42-CA3A-493E-814C-FA1387EA7FA7
P2860
Hydroxyethyl starch: a review of pharmacokinetics, pharmacodynamics, current products, and potential clinical risks, benefits, and use.
description
2014 nî lūn-bûn
@nan
2014年の論文
@ja
2014年学术文章
@wuu
2014年学术文章
@zh-cn
2014年学术文章
@zh-hans
2014年学术文章
@zh-my
2014年学术文章
@zh-sg
2014年學術文章
@yue
2014年學術文章
@zh
2014年學術文章
@zh-hant
name
Hydroxyethyl starch: a review ...... ical risks, benefits, and use.
@en
type
label
Hydroxyethyl starch: a review ...... ical risks, benefits, and use.
@en
prefLabel
Hydroxyethyl starch: a review ...... ical risks, benefits, and use.
@en
P2093
P2860
P356
P1476
Hydroxyethyl starch: a review ...... ical risks, benefits, and use.
@en
P2093
Elke Rudloff
Polly A Glover
Rebecca Kirby
P2860
P304
P356
10.1111/VEC.12208
P577
2014-08-26T00:00:00Z